Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.39 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | STK16 | O75716 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1468584 | 1.00 | AAK1 (0.44) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL1468679 | 0.99 | AAK1 (0.44) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL1468677 | 0.99 | AAK1 (0.44) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| Hydrochloric Acid SCHEMBL1468476 | 0.95 | PIM2 (0.46) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| Hydrochloric Acid SCHEMBL1468479 | 0.95 | PIM2 (0.46) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| Hydrochloric Acid SCHEMBL1469007 | 0.95 | PIM2 (0.46) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL1468799 | 0.94 | PIM2 (0.47) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL29599640 | 0.94 | PIM2 (0.47) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL1470547 | 0.94 | PIM2 (0.47) | AAK1ROCK2ROCK1CDC42BPBPIM2 | |
| SCHEMBL1468800 | 0.94 | PIM2 (0.47) | AAK1ROCK2ROCK1CDC42BPBPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969727-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9365568-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2990407-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2307409-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8981085-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8758830-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8545897-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | ROCK2 1602/4885ROCK1 1293/4885GAA 2075/4885 |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | ROCK2 1602/4885ROCK1 1293/4885GAA 2075/4885 |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | ROCK2 1602/4885ROCK1 1293/4885GAA 2075/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ROCK2 1355/4885ROCK1 1141/4885GAA 1849/4885 |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | ROCK2 1602/4885ROCK1 1293/4885GAA 2075/4885 |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | ROCK2 1602/4885ROCK1 1293/4885GAA 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.